Magseed Pro(R)/ Sentimag(R) Gen3

The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast

Trial Details

NCT ID
NCT05142787
Phase
NA
Sponsor
Endomagnetics Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
Locations (sample)
  • Bottrop, Germany|51.52392,6.9285
  • Frankfurt, Germany|49.68333,10.53333
  • Munich, Germany|48.13743,11.57549
  • London, United Kingdom|51.50853,-0.12574
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Participant is willing and able to give informed consent for participation in the study
  • Participant is aged 18 years or older at the time of consent.
  • Patients requiring breast lesion/axillary node marking and excision

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →